Sabra Health Care REIT falls 1.3% as volume picks up and company sets Q3 reporting date

What happened

Sabra Health Care REIT (SBRA) fell 1.3% on October 19, 2026, after trading volume reached 1.3 times its 20-day average and the company announced the timing of its third-quarter results. The move came during an ordinary session for the stock, while the S&P 500 rose 0.4% and the Real Estate sector median fell 1.7%, leaving the stock 0.3 percentage points better than the sector median.

How big was the move

The stock closed at $19.08, having opened 0.7% below the previous close and finishing the five-session span having fallen 0.6%. Session size measured 1.1 times a typical daily move for the stock, and a beta of 0.11 indicates the stock tends to move less than the market. Trading volume at 1.3 times its 20-day average signaled heavier activity than typical for the session, though by several measures the day was a routine decline rather than a sharp sell-off.

The technical picture

Technically, the stock traded below several key moving averages: it was 1.4% below its 20-day moving average, 4.7% below its 50-day moving average and 4.4% below its 200-day moving average. The 50-day average sits above the 200-day average, which is commonly read as a sign of an established uptrend despite the stock’s recent weakness. The Relative Strength Index (14 days) stood at 39, inside a neutral range between 30 and 70, and the stock was 16.2% below its 52-week high. Over one month the stock fell 3.3% and over three months it fell 13.4%; over one year it rose 7.2%, which left it 8.8 percentage points behind the S&P 500. Volatility was 19% annualized over 60 days, lower than 92% of its own readings over five years, suggesting relatively subdued price swings versus the company’s recent history.

Fundamentals and valuation

For the four quarters through June 30, 2026, revenue was $859.6 million, having grew 17.3% from a year earlier and showing growth of 12.9% versus one quarter earlier. That top-line expansion contrasts with a sharp decline in earnings: diluted earnings per share were $0.26, which fell 65.5% from a year earlier. Gross margin widened to 72.6% from 67.3% a year earlier, while operating margin narrowed to 11.8% from 37.0% a year earlier. Free-cash-flow margin was 40.3% and return on invested capital was 29.1%, metrics that point to solid cash generation and capital efficiency even as reported earnings weakened.

The balance sheet showed net debt of 6.7 times EBITDA, and share count over one year increased by 4.7%. Those items help explain the split between cash-based strength and pressured per-share earnings. On valuation, the stock traded at 72.7 times trailing earnings and 43.7 times expected forward earnings. Its price to trailing earnings was higher than 67% of its own readings over the past five years, with a five-year median of 39.5 times earnings, and free-cash-flow yield was 7.0%. The combination of rapid revenue growth, weak earnings, and a high trailing P/E frames the stock as a growth story that currently carries a rich earnings multiple.

Earnings and analyst expectations

Sabra said it will release its 2026 third quarter earnings after market close on November 2, 2026, and will host a conference call and webcast to discuss results on November 3, 2026, at 10:00 a.m. Pacific Time, according to Business Wire. The company’s last report, on August 3, 2026, showed earnings per share of $-0.10 against $0.17 expected, 158.4% below estimates. The company has recorded zero consecutive quarters beating estimates and the average surprise over the last four reports was 61.6% below estimates. Typical two-day reaction after recent reports was that the stock fell 0.1%.

Analysts place a consensus price target of $21.86, 14.6% above the closing price, based on ratings from 29 analysts. Thirty-eight percent of those ratings were Buy and the consensus rating is Hold. PromtFinance scores rank the company within its sector with Value 35 (Weak), Growth 70 (Positive), Quality 81 (Strong), Momentum 78 (Positive), Revisions 6 (Very weak) and Stability 83 (Strong). Those scores underscore a mix of strengths in growth and quality, offset by weak estimate revisions and a valuation that sits above its historical median.

What to watch

• November 2, 2026: company will release its 2026 third quarter earnings after market close.
• November 3, 2026, at 10:00 a.m. Pacific Time: conference call and webcast to discuss results.
• August 3, 2026: last report showed earnings per share of $-0.10 against $0.17 expected, 158.4% below estimates.
• Consensus price target of $21.86, 14.6% above the closing price.